The goal of this study was to assess the effect of acute or chronic treatment with S5590, a combination of the angiotensin-converting enzyme inhibitor perindopril (0.76 mg/kg/day) and the diuretic indapamide (0.24 mg/kg/day) on renal function in spontaneously hypertensive rats with moderate renal injury.
Introduction
Both angiotensin-converting enzyme inhibitors (ACE-I) and diuretics may profoundly affect renal function, and especially glomerular filtration rate (GFR). Thus, it is possible that, in addition to the previously described cardiovascular effects, such a combination may have additive, and possible deleterious, effects on renal function.
In Dahl salt-sensitive rats, the combination of perindopril with indapamide decreased urinary protein excretion and markedly prevented glomerular injury assessed histologically. 1 However, these effects were tested in a low-renin model, characterised by a relative insensitivity to one of the components of the combination (the ACE-I). Moreover, the Dahl model is also characterised by the development of severe renal injury. In this situation, it is difficult to separate direct functional effects of antihypertensive treatments from the indirect effects, secondary to the structural protective effects. To date, no study has assessed the effects of such combinations on renal blood flow (RBF) and GFR, especially in the absence of marked renal injury.
Thus, the goal of this study was to assess the effect of acute or chronic treatment with S5590 on renal function, evaluated in conscious spontaneously hypertensive rats (SHR), a model characterised by a responsiveness to both ACE-I and diuretics, and by the development of moderate renal injury.
Methods

Animals and treatment
Ten-week-old SHRs and normotensive WKY rats (IFFA-Credo, St Germain sur Arbresle, France) were used. They were acclimatised to the laboratory conditions (temperature 21°C, day/night cycle) for six weeks.They were placed on a normal powder diet (A04, UAR, Villemoisson s/orge), containing 100 µmol Na + /g, with free access to water. At the age of sixteen weeks, the SHR were assigned to three groups: untreated, chronic treatment (six weeks) with S5590, or acute treatment with S5590 (for 24 hours, after six weeks of placebo). WKY rats were treated with placebo.The dose of S5590 was 1 mg/kg/day (perindopril 0.76 + indapamide 0.24 mg/kg/day) and the drug was added to food. Body weight and food consumption were evaluated every week, in order to adapt the concentration of S5590 in the chow.
Experimental design
At the end of the treatment period, rats were briefly anaesthetised with the short-acting anaesthetic agent, methohexital, (50 mg/kg i.p.). The right carotid artery was cannulated with a polyethylene catheter (PE 50, Clay Adams, USA) connected to a pressure transducer and a Gould Windowgraph ® recorder for the recording of blood pressure (BP) and heart rate. The same catheter was also used for collecting blood samples. The right jugular vein was cannulated with an elastomer catheter for injections of saline and of labelled inulin and PAH. Both catheters were tunnelled to the back of the neck and exteriorised. Urine samples were collected via a polyethylene catheter implanted in the bladder.
Each rat was placed in a semi-contention box for recovery. The experimental protocol was carried out in conscious animals. Renal function was evaluated by clearance methods. The rats were immediately infused with 0.9% NaCl solution (1.2 ml/h) and BP and diuresis were allowed to stabilise over a period of 120 minutes. Rats were then infused with a 0.9% NaCl solution containing 0.25 µci/ml 14 C-aminohippuric acid (Du Pont de Nemours, Les Ulis, France), 0.8 µci/ml 3 H-inulin-methoxy (Du Pont de Nemours, Les Ulis, France) and 2.5 mg/ml hippuric acid (Sigma) throughout the experiment.
Rats were left to stabilise for another 60 minutes, after which three urine samples were collected every 30 minutes (T30, T60, T90 minutes). Blood samples (500 µl) were collected at the middle of each period (T15, T45, T75 minutes). After each blood sample, blood loss was compensated by injecting 500 µl blood collected from another rat. Values reported are the average of the measurements from the second and the third periods.
After collection, urine samples were weighed and immediately frozen at -30°C. Blood samples were centrifuged (4000 g, 10 minute), and plasma samples were then immediately frozen at -30°C. During the first period of blood collection, another sample of 500 µl blood was also collected for measuring haematocrit.
The procedure for the care and euthenasia of rats was in accordance with the European Community Standards on the care and use of laboratory animals.
Biochemistry
Urine volume was determined gravimetrically and diuresis was expressed in µl/min. Electrolyte concentrations were measured in fresh urine with an ion-selective electrode (Beckman). Natriuresis and kaliuresis were calculated and expressed in µmol/min. 3 H-inulin and 14 C-aminohippuric acid activities in urine and plasma were counted for each clearance period and used to calculate GFR and renal plasma flow (RPF) from the formula: radioactivity in urine x urinary flow/radioactivity in plasma. Additionally, GFR and RPF were normalised to kidney weight. RBF was calculated from the RPF/(1haematocrit) ratio. Filtration fraction was determined from the formula: GFRx100/RPF. Renal vascular resistances were calculated as the mean BP/RBF ratio.
Statistical analysis
Data are expressed as mean±SEM. Results were analysed by one-way analysis of variance (ANOVA), followed by Tukey's test when ANOVA was significant. A p-value <0.05 was considered statistically significant. 
Results
Effects of hypertension
Mean arterial blood pressure (MABP) was significantly higher in untreated SHR than in normotensive rats (191.3±6.8 vs. 133.1±2.5 mmHg, p<0.001) ( Figure 1 ). Heart rate did not differ between the two groups (Table 1) .
Mean kidney weight was significantly lower in control SHR than in normotensive rats (1.3±0 vs. 1.4±0 g, p<0.03) ( Table 1) .
Diuresis, natriuresis and kaliuresis did not differ between the two groups. However, the two latter parameters tended to be lower in SHR than in normotensive rats ( Figure 2 ).
GFR was moderately, but not significantly, decreased in SHR (1.6±0.3 vs. 1.9±0.3 ml/min/g kidney) ( Figure 3 ). RPF was significantly lower in control SHR than in normotensive rats (2.9±0.4 vs. 4.8±0.7 ml/min/g kidney, p<0.03). RBF was significantly decreased in SHR (5.8±0.9 vs. 8.9±1.2 ml/min/g kidney, p<0.02) (Figure 3 ), while haematocrit was slightly but significantly higher in control SHR (p<0.05).Thus, filtration fraction was significantly higher in control SHR than in normotensive rats (55.7±3.9 vs. 39.9±2.6%, p<0.01) ( Figure 3 ). Control SHR had significantly higher renal vascular resistance (RVR) than normotensive WKY rats (43.9±10.8 vs. 17.6±2.8 mmHg/ml/ min/g kidney, p<0.01) ( Figure 4 ).
Effect of acute treatment with S5590
In SHR, acute treatment with S5590 significantly reduced, but did not normalise, MABP (166.9±4.6 vs. 191.3±6.8 mmHg, p<0.02) (Figure 1 ).
Mean kidney weight did not differ significantly between SHR with acute treatment and untreated SHR. Haematocrit was significantly higher in SHR with acute treatment (p<0.01) ( Table 1) .
Acute treatment slightly but non significantly increased diuresis, natriuresis and kaliuresis ( Figure 2 ). Acute treatment also significantly increased GFR (2.8±0.5 vs. 1.6±0.3 ml/min/g kidney), RPF (5.0±1.0 vs. 2.9±0.4 ml/min/g) and RBF (10.4±2.1 vs. 5.8±0.9 ml/min/g) (p<0.05), and did not affect filtration fraction (61.4±7.1 vs. 55.7±3.9%) ( Figure  3 ).
Finally, acute treatment significantly decreased RVR (21.5±4.6 vs. 43.9±10.8 mmHg/ml/min/g kidney, p<0.05). Mean RVR of SHR with acute treatment did not significantly differ from that of normotensive rats (Figure 4 ).
Effect of chronic treatment with S5590
In SHR, chronic treatment with S5590 significantly reduced MABP (136.7±6.9 vs. 191.3±6.8 mmHg, p<0.01) ( Figure 1 ) while heart rate was not modified ( Table 1) . MABP of SHR with chronic treatment was not significantly different from that of normotensive rats.
Kidney weight did not differ between the two groups. Haematocrit was significantly higher in chronically treated SHR than in untreated SHR (p<0.01) ( Table 1) .
Diuresis, natriuresis and kaliuresis did not differ significantly between the two groups ( Figure 2 ). GFR (1.6±0.3 vs. 1.6±0.3 ml/min/g kidney), RPF (3.8±0.7 vs. 2.9±0.4 ml/min/g), RBF (7.9±1.4 vs. 5.8±0.9 ml/min/g) and filtration fraction (43.1±6.4 vs. 55.7±3.9%) were not significantly different between the two groups ( Figure 3 ). Chronic treatment significantly decreased RVR (20.3±2.7 vs. 43.9±10.8 mmHg/ml/min/g kidney, p<0.02). Mean RVR of SHR with chronic treatment was not significantly different from normotensive rats (Figure 4 ).
Comparison between chronic treatment and acute treatment with S5590 in SHR
MABP was significantly lower in SHR with chronic treatment compared with acute treatment (p<0.01) ( Figure 1 ).
Mean kidney weight and haematocrit did not differ between the two groups (Table 1) .
Diuresis, natriuresis and kaliuresis were slightly but not significantly lower in SHR with chronic treatment compared with acute treatment (Figure 2 ). GFR after chronic treatment was significantly lower than after acute treatment (1.6±0.3 vs. 2.8±0.5 ml/min/g kidney, p<0.05). RBF and filtration fraction were slightly but not significantly lower after chronic treatment (Figure 3 ). RVR did not differ between the two treatment groups (Figure 4 ).
Discussion
In this context, our results show that fixed-dose combination therapy with low doses of perindopril and indapamide decreased MABP and RVR in SHR. Both acute and chronic treatment normalised RVR, although the effect on BP was more marked after chronic than after acute treatment. Moreover, this treatment was well-tolerated in terms of renal function. Indeed, although acute treatment with S5590 increased GFR and RBF, chronic treatment did not affect these parameters. The antihypertensive properties of ACE-I and diuretics are well established. [2] [3] [4] The antihypertensive properties of indapamide are probably related both to its diuretic effects and to direct vascular smooth muscle relaxing properties. [5] [6] [7] [8] [9] Our previous study has shown that combined treatment with low doses of perindopril and indapamide induced a hypotensive effect in SHR which was more marked than that induced by each compound alone. 10 However, ACE-I and diuretics may alter renal function, especially glomerular filtration rate, and this may represent a deleterious effect of such treatment. 11 Thus, it was important to assess the effects of this fixed-dose combination on renal function.
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In SHR, the marked increase in arterial BP was associated with markedly increased RVR and decreased RPF, causing an increase in filtration fraction. GFR and RBF were slightly lower in untreated SHR than in normotensive rats, although the difference was only significant for RBF. Thus, renal function was only slightly modified in SHR. This observation is in accordance with the fact that this model of hypertension is associated with moderate structural renal alterations. 12 Acute treatment with S5590 decreased MABP and RVR, although MABP did not reach the value of normotensive rats. These modifications were associated with increased GFR and RBF, and only slight increases in diuresis and natriuresis.
The modest diuretic and natriuretic effects observed after acute treatment are not surprising, since indapamide has only a moderate diuretic effect, even at doses much higher than those used in this study. 6, 7 Acute ACE inhibition is well known to increase GFR and RBF and indapamide has also been shown to increase these parameters. [13] [14] [15] However, since ACE-I are known to induce vasodilatation of efferent arterioles which is more marked than that of afferent arterioles, and since indapamide probably dilates both types of arterioles to a similar extent, it is likely that intraglomerular pressure is markedly decreased after acute S5590. 11 However, we found a significant increase in glomerular filtration rate, because of the associated increase in RBF. Filtration rate did not change, reflecting the fact that the increase in GFR and the increase in RBF were similar. 16 The marked effect of acute treatment on RBF and RVR is probably related to the renal vasodilatation caused by both indapamide and perindopril.
Thus, in this context of acute treatment, the two components of this combination are synergistic and have a beneficial effect on renal function.
During chronic treatment with S5590, despite the marked decrease and normalisation of MABP and RVR, there was no change in GFR, RBF, diuresis or natriuresis.
Our data suggest that chronic treatment with S5590 has a protective effect on renal function. GFR and RBF in rats chronically treated with S5590 were not different from those of untreated GFR (ml/min/g kidney) SHR, despite a decreased amount of water (attested by decreased body weight and increased haematocrit) which might be related to the diuretic effect of indapamide.Thus, it is possible that the decreased RBF, secondary to the diuretic action of indapamide, was compensated by the marked vasodilatation induced by the indapamideperindopril combination and resulted in no significant change in filtration fraction. [17] [18] [19] [20] [21] This might explain why filtration fraction was not decreased although a reduction could have been expected, based on previous data obtained with ACE-I. 4, 11, 13, 14 Given the fact that chronic treatment with S5590 induced a marked decrease in arterial pressure, it is important to note that glomerular filtration can be maintained only in a context in which efferent arteriolar vasodilation is more marked than afferent arteriolar vasodilatation. In this case, this differential vasodilatation can be ascribed to the ACE-I, since the vasoconstrictor effects of angiotensin II are more marked at the level of the efferent than of the afferent arterioles.
In conclusion, acute and chronic treatment with S5590, the combination of low doses of the ACE-I perindopril and the diuretic/vasodilator indapamide, induced a marked renal vasodilatation, without significant adverse effects on renal function.The maintenance of GFR and filtration fraction after chronic treatment, which occurs in a setting of normalisation of arterial pressure, and the normalisation of RVR suggest that such a combined treatment may exert marked renal functional protective effects in hypertension.
